FDA Standard Drug Review Goals Could be Lengthened By 1-2 Months, IG Says
This article was originally published in The Tan Sheet
Executive Summary
FDA should consider extending by one or two months its 10-month goal for standard drug reviews, the HHS Inspector General said in a 1report released March 25
You may also be interested in...
John Taylor Temporarily Replaces Sharfstein As FDA's Second-In-Command
John Taylor, counselor to FDA Commissioner Margaret Hamburg, will serve temporarily as second-in-command while Hamburg considers how to reorganize the agency's leadership following Principal Deputy Commissioner Josh Sharfstein's departure.
FDA “Refuse-To-File” Decisions Encouraged For Incomplete, Poor NDAs – IG
FDA should consider issuing "refuse-to-file" decisions more often for incomplete or inadequate NDAs, the HHS Inspector General recommended in a report released March 25
FDA “Refuse-To-File” Decisions Encouraged For Incomplete, Poor NDAs – IG
FDA should consider issuing "refuse-to-file" decisions more often for incomplete or inadequate NDAs, the HHS Inspector General recommended in a report released March 25